Tradestie Institutional Equity Comparison Engine

FDMT vs BMRN โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

BMRN Overall Edge

BMRN Captures Institutional Edge (3โ€“1 Pillars ยท 8โ€“2 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to BioMarin Pharmaceuticals Inc (BMRN) driven by superior Valuation, Growth & Margin, Options & Structure while FDMT counters with relative strength in Momentum & Technical. Fundamentally, FDMT trades at N/M Forward P/E with -222.7% operating margin (+4505.6% YoY revenue) versus BMRN at 9.1x Forward P/E and 16.3% operating margin (+32.0% YoY). In options structure, FDMT sits in BREAKDOWN (10th %ile IV; Dealer Gamma Walls on Pro) against BMRN sits in CONSOLIDATION (17th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner BMRN
FDMT N/M vs BMRN 9.1x Fwd P/E
Growth & Margin Winner BMRN
Op Margin -222.7% vs 16.3% ยท YoY +4505.6% vs +32.0%
Momentum & Technical Winner FDMT
1Y +13.3% vs +7.6% ยท 52W Pos 47% vs 42%
Options & Structure Winner BMRN
BREAKDOWN (10th %ile IV) vs CONSOLIDATION (17th %ile IV)
FDMT NASDAQ
4D Molecular Therapeutics, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$11.65
-4.74% 1D
Market Cap $669.3M
1M Return -4.04%
1Y Return +13.33%
Forward P/E N/M
Unified AI Score
42.1 / 100 HOLD
Tech 21.0 Fund 54.0 Flow 66.0 Mom 54.0
BMRN NASDAQ
BioMarin Pharmaceuticals Inc
Pharmaceutical Preparations
$58.32
+1.9% 1D
Market Cap $11.0B
1M Return +6.66%
1Y Return +7.56%
Forward P/E 9.1x
Unified AI Score
52.3 / 100 HOLD
Tech 56.0 Fund 61.0 Flow 67.0 Mom 60.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: FDMT +13.33% BMRN +7.56% Spread: +5.77 pp (FDMT Lead)

Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant Revenue ($B) & Operating Margin (%)
Period FDMT Revenue BMRN Revenue FDMT Op. Margin BMRN Op. Margin Margin Edge
FY2018 N/A $1.49B N/A -8.3% BMRN
FY2019 $10M $1.70B -729.4% -5.9% BMRN
FY2020 $10M $1.86B -424.0% -2.3% BMRN
FY2021 $20M $1.85B -395.5% -4.5% BMRN
FY2022 $0M $2.10B -3516.5% 7.7% BMRN
FY2023 $20M $2.42B -544.6% 7.7% BMRN
FY2024 $0M $2.85B -507678.4% 17.0% BMRN
FY2025 $90M $3.22B -187.2% 12.7% BMRN

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: FDMT (2) vs BMRN (8)
Institutional Metric FDMT BMRN Criterion Row Winner
Market Capitalization Scale $669.3M $11.0B Larger Scale BMRN
Trailing P/E Ratio Valuation N/M 8.8x Lower Multiple BMRN
Forward P/E Ratio Valuation N/M 9.1x Lower Multiple BMRN
Revenue Growth (YoY) Growth +4505.6% +32.0% Higher Growth FDMT
Operating Margin (TTM) Profitability -222.7% 16.3% Higher Margin BMRN
Net Profit Margin Profitability -208.6% -0.5% Higher Margin BMRN
Return on Equity (ROE) Capital Efficiency -56.7% -0.3% Higher ROE BMRN
52-Week Range Position Momentum 47% ($7โ€“$17) 42% ($49โ€“$71) Stronger Trend FDMT
Beta / 30D Volatility Risk Regime 1.89ฮฒ ยท 90% Vol 0.28ฮฒ ยท 31% Vol Lower Realized Risk BMRN
Unified Institutional Score Composite Signal 42.1 / 100 (HOLD) 52.3 / 100 (HOLD) Higher Composite BMRN

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full FDMT vs BMRN Buy Guide
FDMT BREAKDOWN
62d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 10th %ile
IV Regime Compressed (<25th %ile)
Live FDMT Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
BMRN CONSOLIDATION
67d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 17th %ile
IV Regime Compressed (<25th %ile)
Live BMRN Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither FDMT nor BMRN registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.